Veterans' Health and PTSD Treatment

President Donald Trump is reportedly weighing an executive order intended to accelerate U.S. research into ibogaine, a psychedelic compound used abroad to treat post-traumatic stress disorder, with the stated goal of expanding scientific study and potential access for veterans and service members. The move comes amid mounting evidence of unmet need: in fiscal year 2024 roughly 14% of male veterans and 24% of female veterans were diagnosed with PTSD, and nearly 26% of service members and veterans discontinue PTSD therapy, especially trauma-focused treatments. Demand for off-shore ibogaine treatment is already evident — thousands of Americans have traveled to clinics in Mexico for ibogaine-assisted care, with one facility reporting more than 3,000 patients treated — a pattern proponents point to as evidence of both need and interest.